150 related articles for article (PubMed ID: 27685842)
1. Is the Noradrenergic Symptom Cluster a Valid Construct in Adjunctive Treatment of Major Depressive Disorder?
Stauffer VL; Liu P; Goldberger C; Marangell LB; Nelson C; Gorwood P; Fava M
J Clin Psychiatry; 2017 Mar; 78(3):317-323. PubMed ID: 27685842
[TBL] [Abstract][Full Text] [Related]
2. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
3. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
[TBL] [Abstract][Full Text] [Related]
5. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
Ball SG; Atkinson S; Sparks J; Bangs M; Goldberger C; Dubé S
J Clin Psychopharmacol; 2015 Jun; 35(3):266-72. PubMed ID: 25815754
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
Lin DY; Kratochvil CJ; Xu W; Jin L; D'Souza DN; Kielbasa W; Allen AJ
J Child Adolesc Psychopharmacol; 2014 May; 24(4):190-200. PubMed ID: 24840045
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder.
Jin L; Xu W; Krefetz D; Gruener D; Kielbasa W; Tauscher-Wisniewski S; Allen AJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):200-7. PubMed ID: 23607409
[TBL] [Abstract][Full Text] [Related]
8. Long-Term, Open-Label, Safety Study of Edivoxetine Monotherapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Nery ESM; Bangs M; Liu P; Ahl J; Perahia D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):700-707. PubMed ID: 28402139
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
[TBL] [Abstract][Full Text] [Related]
10. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
[TBL] [Abstract][Full Text] [Related]
12. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
Blier P; Gommoll C; Chen C; Kramer K
J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
[TBL] [Abstract][Full Text] [Related]
13. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder.
Martinez JM; Ferguson MB; Pangallo BA; Oakes TM; Sparks J; Dellva MA; Zhang Q; Liu P; Bangs M; Ahl J; Goldberger C
Drugs Context; 2015; 4():212279. PubMed ID: 26005493
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder.
Iovieno N; Shelton RC; Petrie SR; Cusin C; Fava M; Papakostas GI
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 28749091
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
[TBL] [Abstract][Full Text] [Related]
17. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
Fava M; Dirks B; Freeman MP; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
J Clin Psychiatry; 2019 Sep; 80(6):. PubMed ID: 31556975
[TBL] [Abstract][Full Text] [Related]
20. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
